| Project/Area Number |
26462598
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Otorhinolaryngology
|
|---|
| Research Institution | Fukushima Medical University (2016)
Kanazawa University (2014-2015) |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
YOSHIZAKI Tomokazu 金沢大学, 医学系, 教授 (70262582)
WAKISAKA Naohiro 金沢大学, 医学系, 准教授 (70377414)
KONDO Satoru 金沢大学, 大学病院, 講師 (70436822)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 喉頭乳頭腫 / HPV / VEGF / 血管新生 / うがい液 |
|---|
| Outline of Final Research Achievements |
Recurrent respiratory papillomatosis (RRP) is a refractory human papillomavirus (HPV)-associated disease. We tried to establish a tissue culture model of RRP. We confirmed growth of tumor cells in the primary tissue culture. However, continuing growth of those cells could not be achieved in following passage. On the other hand, immunohistochmestry was also performed to investigate a factor for a novel therapy. Expression of vascular endothelial growth factor (VEGF) was observed around fibrovascular cores of RRP. VEGF was observed in cores without an obvious vascular structure. Therefore, anti-VEGF antibody therapy can be a candidate for a novel therapy of RRP.
|
